Vanda Pharmaceuticals (VNDA) Cash & Equivalents (2009 - 2026)

Vanda Pharmaceuticals has disclosed Cash & Equivalents across 18 years of filings, most recently posting $54.0 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $54.0 million, down 51.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $54.0 million (down 51.67% YoY), and the FY2025 annual result was $84.9 million, down 17.07% from the prior year.
• Cash & Equivalents came in at $54.0 million for Q1 2026 at Vanda Pharmaceuticals, down from $84.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $354.2 million in Q1 2023 to a low of $49.4 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $102.3 million (2024), against an average of $115.6 million.
• Across the five-year window, Cash & Equivalents jumped 429.19% in 2023 and plunged 64.66% in 2024, its largest moves.
• Vanda Pharmaceuticals' Cash & Equivalents stood at $135.0 million in 2022, then advanced by 0.59% to $135.8 million in 2023, then declined by 24.67% to $102.3 million in 2024, then declined by 17.07% to $84.9 million in 2025, then plunged by 36.32% to $54.0 million in 2026.
• The last three Cash & Equivalents figures came in at $54.0 million (Q1 2026), $84.9 million (Q4 2025), and $70.0 million (Q3 2025), per Business Quant data.